Keranova

Executive Summary

KERANOVA is a French medical device company pioneering the next generation of ophthalmic surgical systems through its proprietary photonics-based ultra-fast laser platform, FemtoMatrix®. Founded in 2015, the company aims to revolutionize cataract surgery by enabling fully programmable, automated procedures with minimal human intervention. Traditional cataract surgery relies on manual phacoemulsification and handheld lasers, which are limited by precision, reproducibility, and surgeon dependency. Keranova’s technology leverages advanced photonics to deliver femtosecond laser pulses with unprecedented speed and accuracy, allowing for customized corneal incisions, capsulorhexis, and lens fragmentation in a single, software-driven step. This approach promises to reduce surgical time, enhance safety, and improve outcomes while lowering the barrier to high-quality cataract care globally. The system addresses a growing market driven by aging populations and increasing demand for refractive precision. Despite its innovative potential, Keranova operates as a private company with limited public disclosure of funding, clinical data, or regulatory timelines. Its stage appears to be early clinical or pre-commercial, with no confirmed partnerships or revenue. The competitive landscape includes established femtosecond laser platforms from Alcon (LenSx) and Johnson & Johnson (Catalys), but Keranova’s all-photonics design may offer differentiation in speed, footprint, and cost. Conviction in the company is tempered by the lack of published clinical evidence and regulatory milestones. Near-term progress will depend on successful device validation, regulatory submissions, and strategic collaborations to navigate the capital-intensive ophthalmic device market.

Upcoming Catalysts (preview)

• Q4 2026CE Mark Approval for FemtoMatrix60% success
• Q2 2026First Clinical Study Enrollment70% success
• H2 2026Strategic Partnership with Major Ophthalmic Company40% success